Corline Biomedical AB Working Capital to Net Assets Ratio
Corline Biomedical AB working capital to net assets ratio. Corline Biomedical AB (CLBIO) has a Working Capital to Net Assets ratio of 33.5% as of June 2026. Working capital of Skr33.20 Million (current assets of Skr39.25 Million minus current liabilities of Skr6.05 Million) is measured against net assets of Skr99.00 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Corline Biomedical AB (2012–2025)
Working capital to net assets ratio of Corline Biomedical AB from 2012 to 2025. This chart shows how Corline Biomedical AB's Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of June 2026, the ratio stands at 33.5%, reflecting working capital of Skr33.20 Million against net assets of Skr99.00 Million SEK. See Corline Biomedical AB defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Corline Biomedical AB Working Capital to Net Assets Ratio by Year (2012–2025)
Corline Biomedical AB working capital to net assets ratio by year from 2012 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Corline Biomedical AB from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Corline Biomedical AB (CLBIO) total assets.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 20.4% | Skr19.16 Million | Skr93.76 Million | Skr23.98 Million | Skr4.82 Million | ▲ +5.3 pp |
| 2024 | 15.2% | Skr13.20 Million | Skr86.91 Million | Skr21.04 Million | Skr7.85 Million | ▼ -3.0 pp |
| 2023 | 18.2% | Skr17.01 Million | Skr93.32 Million | Skr23.80 Million | Skr6.79 Million | ▼ -12.2 pp |
| 2022 | 30.5% | Skr28.80 Million | Skr94.59 Million | Skr36.00 Million | Skr7.19 Million | ▼ -7.9 pp |
| 2021 | 38.4% | Skr35.39 Million | Skr92.23 Million | Skr44.82 Million | Skr9.43 Million | ▲ +29.7 pp |
| 2020 | 8.6% | Skr4.49 Million | Skr52.03 Million | Skr10.74 Million | Skr6.25 Million | ▼ -26.0 pp |
| 2019 | 34.7% | Skr20.56 Million | Skr59.32 Million | Skr24.99 Million | Skr4.43 Million | ▼ -3.6 pp |
| 2018 | 38.3% | Skr21.04 Million | Skr54.96 Million | Skr28.99 Million | Skr7.95 Million | ▲ +10.1 pp |
| 2017 | 28.2% | Skr12.94 Million | Skr45.93 Million | Skr18.44 Million | Skr5.50 Million | ▲ +0.4 pp |
| 2016 | 27.8% | Skr10.78 Million | Skr38.75 Million | Skr13.31 Million | Skr2.53 Million | ▲ +19.3 pp |
| 2015 | 8.6% | Skr1.82 Million | Skr21.25 Million | Skr5.56 Million | Skr3.74 Million | ▲ +175.0 pp |
| 2014 | -166.5% | Skr-9.13 Million | Skr5.48 Million | Skr2.16 Million | Skr11.29 Million | ▼ -120.6 pp |
| 2013 | -45.9% | Skr-3.67 Million | Skr8.00 Million | Skr1.83 Million | Skr5.50 Million | ▲ +500.7 pp |
| 2012 | -546.6% | Skr-7.50 Million | Skr1.37 Million | Skr3.59 Million | Skr11.09 Million | — |